Stock AnalizNeogen Corp. NEOG
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 1989 · data as of November 13, 2026
Neogen Corp. (NEOG) is a healthcare company listed in the US with a market value of about $2.5B. In the twelve months to August 31, 2026 it had revenue of $884M and net income of -$56M, a net margin of -6.3%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 49.2, 5-year revenue growth of 13% a year, a 5-year average ROIC of -6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.
Score: 1.0 / 5
Checks passed
- Profit margin improving
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $884M | $870M | $895M | $924M | $822M | $527M | $468M | $418M | $414M | $398M | $358M |
| Net income | -$56M | -$8M | -$1.1B | -$9M | -$23M | $48M | $61M | $59M | $60M | $63M | $44M |
| Free cash flow | $50M | $32M | -$46M | -$76M | -$25M | $44M | $54M | $62M | $49M | $48M | $46M |
| EPS (diluted) | $-0.26 | $-0.04 | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 | $0.56 | $0.57 | $0.60 | $0.43 |
| Net margin | -6.3% | -0.9% | -122.0% | -1.0% | -2.8% | 9.2% | 13.0% | 14.2% | 14.5% | 15.9% | 12.2% |
| ROIC | — | -0.7% | -34.2% | 0.9% | 0.6% | 5.3% | 7.1% | 7.6% | 8.8% | 10.8% | 9.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $14.00, 25% above the current price; targets range from $14.00 to $14.00; the consensus rating is “Buy”; expected EPS is $0.33 for the fiscal year ending May 31, 2027.
Frequently asked questions
Is Neogen stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Neogen pay a dividend?
Not currently.
Is Neogen a good stock to buy?
We do not give buy or sell advice. Neogen scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.